Cancer Science Institute of Singapore (CSI)

A Premier Centre for Cutting Edge Cancer Research.

A dynamic research institute encompassing basic and translational studies, devoted to understanding the pathogenesis and treatment of cancer
null

(Pharmacol Res, Feb 2020)

A Unique CDK4/6 Inhibitor: Current and Future Therapeutic Strategies of Abemaciclib.

  Read More

null

(Cell Rep, Feb 2020)

A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity.

  Read More

null

(Nat Commun, Feb 2020)

Cis- and Trans-Regulations of Pre-mRNA Splicing by RNA Editing Enzymes Influence Cancer Development.

  Read More

null

CSI Singapore congratulates Dr. Takaomi Sanda on this award!

Yong Loo Lin School of Medicine Research Excellence Award AY2018/2019

  Read More

null

(Blood, Jan 2020)

Feed-forward Regulatory Loop Driven by IRF4 and NF-kB in Adult T-cell Leukemia/Lymphoma.

  Read More

null

(Gut, Jan 2020)

DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.

  Read More

Giving to CSI

You can help us to shape the next generation of innovative cancer research

null
Epigenetics in Cancer Symposium 2020
Learn More

Upcoming Events

null

7th NCIS Annual Research Meeting
24 - 25 July 2020

  Read More

null

Cancer Treatment Advances: At what cost?
1 October 2020

  Read More

null

RNA Biology Symposium 2020
1 - 2 October 2020

  Read More